Otonomy Inc News - OTIC

Otonomy Provides Corporate Update

SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s...

Current Report Filing (8-k)

false 0001493566 0001493566 2022-11-14 2022-11-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Amended Statement of Ownership (sc 13g/a)

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities...

Quarterly Report (10-q)

2http://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us...

Current Report Filing (8-k)

false0001493566OTONOMY, INC.00014935662022-11-102022-11-10 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549...

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company...

Current Report Filing (8-k)

false 0001493566 0001493566 2022-10-14 2022-10-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from...

Current Report Filing (8-k)

OTONOMY, INC.false000149356600014935662022-08-032022-08-03 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549...

Statement of Ownership (sc 13g)

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto...

Analyst Explains Why They Downgraded Their Rating on Otonomy (OTIC)

H.C. Wainwright analyst Oren Livnat downgraded Otonomy (OTIC – Research Report) to Hold today. The company's shares closed last Monday at $0.29...

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints...

Quarterly Report (10-q)

http://www.otonomy.com/20220630#LeaseLiabilitiesNonCurrenthttp://www.otonomy.com/20220630#LeaseLiabilitiesCurrenttruehttp://fasb.org/us-gaap/2022...

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed...

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Otonomy Inc (OTIC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

OTIC News

Otonomy Provides Corporate Update

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Current Report Filing (8-k)

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Analyst Explains Why They Downgraded Their Rating on Otonomy (OTIC)

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

Quarterly Report (10-q)

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

OTIC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Otonomy Inc (OTIC) News

Otonomy Inc (OTIC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

OTIC News

Otonomy Provides Corporate Update

Current Report Filing (8-k)

Amended Statement of Ownership (sc 13g/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Current Report Filing (8-k)

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Analyst Explains Why They Downgraded Their Rating on Otonomy (OTIC)

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

Quarterly Report (10-q)

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

OTIC Discussion

Your Recent History